Search For

Ivosidenib enhances cisplatin sensitivity in ovarian cancer by reducing cancer cell stemness

Ovarian tumor microenvironment contributes to tumor progression and chemoresistance

Unlocking the potential of immunotherapy in platinum-resistant ovarian cancer: rationale, challenges, and novel strategies

Novel players in the development of chemoresistance in ovarian cancer: ovarian cancer stem cells, non-coding RNA and nuclear receptors

A comprehensive overview of recent developments on the mechanisms and pathways of ferroptosis in cancer: the potential implications for therapeutic strategies in ovarian cancer

The clinical challenges of homologous recombination proficiency in ovarian cancer: from intrinsic resistance to new treatment opportunities

Immune checkpoint inhibitors in ovarian cancer: where do we go from here?

The evolving role of DNA damage response in overcoming therapeutic resistance in ovarian cancer

Ovarian cancer resistance to PARPi and platinum-containing chemotherapy

A patient with relapsed high-grade serous ovarian carcinoma with somatic RAD51C mutations treated with PARPi monotherapy: a case report

Ovarian cancer recurrence: “is the definition of platinum resistance modified by PARP inhibitors and other intervening treatments?”

Ovarian cancer recurrence: is the definition of platinum resistance modified by PARPi and other intervening treatments? The evolving landscape in the management of platinum-resistant ovarian cancer